deLIVER: Direct Acting Antiviral Effects on the Liver

• Sponsor: Johns Hopkins University (Other)
• Overall Status: Completed
• CT.gov ID: NCT02938013
• Collaborator: (none)
• Enrollment: 15
• Location: 1
• Arms: 3
• Actual Duration (Months): 44.9
• Patients Per Site Per Month: 0.3

Study Details

Study Description

Brief Summary

Open-label, partially-randomized plasma and liver sampling study to assess hepatitis C virus (HCV) kinetics during treatment with two (Sofosbuvir/Velpatasvir) or three (Sofosbuvir/Velpatasvir/Voxilaprevir) direct acting antivirals (DAAs)

Condition or Disease	Intervention/Treatment	Phase
HCV Coinfection; Liver Disease; HIV	Drug: Sofosbuvir/Velpatasvir/Voxilaprevir [SOF/VEL/VOX]; Drug: Sofosbuvir/Velpatasvir (SOF/VEL)	Phase 4

Detailed Description

Primary Objective: The primary objective is to estimate the 1-week change in the proportion of HCV-infected hepatocytes in participants with HCV monoinfection and HIV/HCV coinfection on therapy with two or three DAAs with different mechanisms of action using single cell laser microdissection (scLCM).

Secondary Objectives:

Estimate the change over the first week in plasma HCV RNA in subjects with HCV monoinfected and HIV/HCV coinfected participants on therapy with two or three DAAs

Estimate the 1 week change in the amount of HCV RNA per infected hepatocyte using scLCM on liver biopsy specimens, obtained just prior to treatment initiation (pre-treatment), and after the first week of DAA therapy.

Estimate the change in the proportion of HCV-infected hepatocytes that express interferon-stimulated genes (ISGs) within the first week of DAA therapy using scLCM.

Measure the change in expression of ISGs in non-parenchymal intrahepatic immune cells (Kupffer cells, plasmacytoid dendritic cells) within the first week of DAA therapy using scLCM.

Exploratory Objectives:

Estimate the 1 week change in expression of ISGs from peripheral blood mononucleated cells (PBMCs) within the first week of DAA+ribavirin (RBV) therapy using scLCM.

Compare sequence(s) of HCV protease, nonstructural protein 5A (NS5A), and nonstructural protein 5B (NS5B) depending on the peripheral sequence) of intrahepatic HCV RNA in single cells and bulk tissue, before and during week 1 of DAA+RBV therapy.

Estimate the week 1 change in the sizes and numbers of HCV-infected clusters on DAA therapy to test whether clearance of HCV-infected hepatocytes occurs in spatially random patterns or within specific clusters.

Study Design

• Study Type: Interventional
• Actual Enrollment: 15 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: deLIVER: Direct Acting Antiviral Effects on the Liver
• Actual Study Start Date: Jan 1, 2017
• Actual Primary Completion Date: Sep 30, 2019
• Actual Study Completion Date: Sep 30, 2020

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Group A Monoinfected: Sofosbuvir/Velpatasvir/Voxilaprevir SOF/VEL/VOX days 0-7 Paired liver biopsy at days 0 and 7 (cohort 1) or days 0 and 4 (cohort 2). SOF/VEL days 8 (week 2) through 84 (week 12). Post-treatment follow up through week 12.	Drug: Sofosbuvir/Velpatasvir/Voxilaprevir [SOF/VEL/VOX]; antiviral therapy for HCV
Active Comparator: Group B Monoinfected: Sofosbuvir/Velpatasvir (SOF/VEL) days 0 through 7 and Paired liver biopsy at days 0 and 7 (cohort 1) or days 0 and 4 (cohort 2). SOF/VEL on day 8 (week 2) through 84 (week 12) . Post-Treatment follow up through week 12.	Drug: Sofosbuvir/Velpatasvir (SOF/VEL); antiviral therapy for HCV
Active Comparator: Group C HIV/HCV Co-infection: Sofosbuvir/Velpatasvir (SOF/VEL) days 0 through 7 and Paired liver biopsy at days 0 and 7 (cohort 1) or days 0 and 4 (cohort 2). SOF/VEL on day 8 (week 2) through 84 (week 12) . Post-Treatment follow up through week 12.	Drug: Sofosbuvir/Velpatasvir (SOF/VEL); antiviral therapy for HCV

Outcome Measures

Primary Outcome Measures

1. Total Number of HCV-infected Hepatocytes Measured in Liver Tissue Obtained by Liver Biopsy at Day 0 (Pre-treatment) and at Day 7 of Antiviral Therapy [Pre-treatment, Day 7]

   Estimate the total number of HCV-infected Hepatocytes (virus burden) for each participant between pre-treatment liver biopsy and post treatment liver biopsy samples using HCV Quantitative real time PCR. Comparison of total number of HCV-infected Hepatocytes (virus burden) were reported between HCV mono infection and co infection groups.

Secondary Outcome Measures

1. Reduction Over the First Week in Plasma HCV RNA [Pre-treatment, up to 1 week]

   During one week after treatment with direct-acting antivirals, the decline from the baseline plasma HCV RNA levels observed for each individual participant using HCV Quantitative real time PCR. The level of HCV RNA decline compared to those treated with Sofosbuvir/Velpatasvir (SOF/VEL) vs Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) and between HCV mono infection and HIV/HCV co infection groups.

2. Total Number of HCV-infected Hepatocytes That Express Interferon-stimulated Genes (ISGs) Within the First Week of DAA Therapy Using Single Cell Laser Micro Dissection (scLCM). [Pre-treatment, up to 1 week]

   Total number of hepatocytes that express interferon-stimulated genes (ISGs) were estimated using Quantitative real time PCR for each participant on pre-treatment and post treatment liver biopsy samples. Comparison of total number of hepatocytes that express interferon-stimulated genes (ISGs) were reported between HCV mono infection and co infection groups.

3. Amount of HCV RNA Per Infected Hepatocyte Using Single Cell Laser Micro Dissection (scLCM) on Liver Biopsy Specimens, Obtained Just Prior to Treatment Initiation (Pre-treatment), and After the First Week of DAA Therapy. [Pre-treatment, after first week]

   The HCV RNA levels (viral burden) from each infected hepatocytes were measured using Quantitative Real-Time Polymerase Chain Reaction (PCR) from each participants at pre-treatment and post-treatment. The level of HCV RNA (viral burden) decline were reported from intracellular hepatocytes and compared to those treated with Sofosbuvir/Velpatasvir (SOF/VEL) vs Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) and between HCV mono infection and HIV/HCV co infection groups.

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years to 70 Years
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria Participants must meet all of the following inclusion criteria to be eligible for participation

1. Ability and willingness of participant to provide written informed consent.

2. Men and women age ≥18 to ≤70 years at study entry

3. Body mass index (BMI) ≥ 18 kg/m2

4. HCV RNA ≥ 10,000 IU/mL at Screening

5. HCV genotype 1a at Screening or within 6 months of screening

6. Chronic HCV infection (≥ 6 months) documented by prior medical history

7. HCV treatment-naïve with no prior treatment with any IFN, RBV, or approved or experimental HCV-specific DAA

8. Absence of cirrhosis as defined as transient elastography (FibroScan®) liver stiffness measurement < 12.5 kPa within 6 months of screening

9. The following laboratory values obtained within 42 days prior to study entry. • Hemoglobin > 10 g/dL for men and > 9 g/dL for women

• Platelet count ≥90,000/mm3

• International normalized ratio (INR) ≤1.5

• Calculated creatinine clearance (CrCl) ≥ 30 mL/min

• Alanine aminotransferase (ALT) and aspartate aminotransferase level ≤ 10 x upper limit of the normal range (ULN)

• Total bilirubin <3 mg/dL

• Albumin ≥3.5 g/dL

• CD4+ cell count ≥200 cells/uL and CD4+ cell percentage ≥14% within 42 days of study entry at any US laboratory that has a Clinical Laboratory Improvement Amendments (CLIA) certification [HIV seropositive participants only]

• HIV RNA < 400 copies/mL prior to study entry by any US laboratory that has a CLIA certification or its equivalent [HIV seropositive participants only]

1. On a qualifying antiretroviral therapy (ART) regimen which is permitted with SOF/VEL. This allows for antiretroviral regimen that does not include Efavirenz, Nevirapine, or Tipranavir.

2. Women of childbearing potential must have a negative serum pregnancy test at Screening and a negative urine pregnancy test on Day 0 prior to liver biopsy

3. All participants must agree not to participate in a conception process (e.g., active attempt to become pregnant or to impregnate, sperm donation, in vitro fertilization).

4. If participating in sexual activity that could lead to pregnancy, the participant (men and women) must also agree to use two reliable methods of contraception simultaneously while receiving study treatment and for 30 days after stopping study treatment.

A combination of TWO of the following contraceptives MUST be used appropriately:

• Condoms (male or female) with or without a spermicidal agent

• Diaphragm or cervical cap with spermicide

• IUD (intrauterine device)

1. Participants who are not of reproductive potential (women who have been post-menopausal for at least 24 consecutive months or have undergone hysterectomy, bilateral tubal ligation, and/or bilateral oophorectomy or men who have documented azoospermia) are eligible without requiring the use of contraceptives. Acceptable documentation of sterilization and menopause is specified below.

Written or oral documentation communicated by clinician or clinician's staff of one of the following:

• Physician report/letter

• Laboratory report of azoospermia

• Follicle stimulating hormone-release factor (FSH) measurement elevated into the menopausal range as established by the reporting laboratory.

1. Participants must be able to adhere to dosing instructions for study drug administration and able to complete the study schedule of assessments, in the opinion of the investigator.

Exclusion Criteria

Subjects who meet any of the following exclusion criteria are not to be enrolled in this study:

1. Breastfeeding.

2. Known allergy/sensitivity or any hypersensitivity to components of study drugs or their formulation.

3. Acute or serious illness requiring systemic treatment and/or hospitalization within 42 days prior to study entry.

4. Active hepatitis B infection (positive HBsAg) within 42 days prior to study entry.

5. History of decompensated liver disease (including but not limited to encephalopathy, variceal bleeding, or ascites) prior to study entry.

6. Any cause of liver disease other than chronic HCV infection, including but not limited to the following:

• Hemochromatosis

• Alpha-1 antitrypsin deficiency

• Wilson's disease

• Autoimmune hepatitis

• Alcoholic liver disease

• Drug-related liver disease

1. Uncontrolled or active depression or other psychiatric disorder within 24 weeks prior to study entry that in the opinion of the investigator might preclude adherence to study requirements.

2. Active drug or alcohol use or dependence that, in the opinion of the investigator, would interfere with adherence to study requirements.

3. Serious illness including uncontrolled seizure disorders, active coronary artery disease within 24 weeks prior to study entry, or other chronic medical conditions that in the opinion of the investigator might preclude completion of the protocol.

4. Presence of active or acute AIDS-defining opportunistic infections within 12 weeks prior to study entry.

5. Active or history of malignancy within 2 years prior to study entry other than basal cell carcinoma of the skin and/or cutaneous Kaposi's sarcoma (KS) and/or cervical or anal dysplasia or carcinoma in situ.

6. Infection with any HCV genotype other than genotype 1a, or mixed genotype infection any time prior to study entry.

7. History of major organ transplantation with an existing functional graft any time prior to study entry.

8. History of acquired or hereditary bleeding disorder (e.g., hemophilia, warfarin use) or any other cause of or tendency toward excessive bleeding time prior to study entry.

9. Gastrointestinal disorder or post-operative condition that could interfere with the absorption of the study drug 17. Difficulty with blood collection and/or poor venous access for the purposes of phlebotomy 18. Planning to take any of the following medications or supplements from Day -7 to the end of treatment:

10. Proton pump inhibitors (patients may switch to H2 blockers up to Day -7)

11. Inducers of P-gp (including, but not limited to, dexamethasone, morphine, ritonavir, saquinavir, tipranavir)

12. Moderate to potent inducers of CYP2B6, CYP2C8, or CYP3A4 (including, but not limited to, efavirenz, etavirine, modafinil, rifampin, St. John's Wort, carbamazepine, phenytoin) 19. History of taking any dose of amiodarone within 6 months (180 days) of Day 0

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Johns Hopkins Hospital : The John G. Bartlett Specialty Practice	Baltimore	Maryland	United States	21287

Sponsors and Collaborators

• Johns Hopkins University

Investigators

• Principal Investigator: Mark Sulkowski, M.D., Johns Hopkins University

Study Documents (Full-Text)

• Study Protocol and Statistical Analysis Plan - Aug 30, 2017

More Information

Publications

None provided.

• Responsible Party: Johns Hopkins University
• ClinicalTrials.gov Identifier: NCT02938013
• Other Study ID Numbers: IRB00110677
• First Posted: Oct 19, 2016
• Last Update Posted: Feb 24, 2022
• Last Verified: Oct 1, 2020

• Individual Participant Data (IPD) Sharing Statement: No
• Plan to Share IPD: No
• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No
• Additional relevant MeSH terms: Coinfection; Liver Diseases; Sofosbuvir; Velpatasvir; Sofosbuvir-velpatasvir drug combination

Study Results

Participant Flow

Arm/Group Title	Group A	Group B	Group C
Arm/Group Description	Monoinfected: Sofosbuvir/Velpatasvir/Voxilaprevir SOF/VEL/VOX days 0-7 Paired liver biopsy at days 0 and 7 (cohort 1) or days 0 and 4 (cohort 2). SOF/VEL days 8 (week 2) through 84 (week 12). Post-treatment follow up through week 12.	Monoinfected: Sofosbuvir/Velpatasvir (SOF/VEL) days 0 through 7 and Paired liver biopsy at days 0 and 7 (cohort 1) or days 0 and 4 (cohort 2). SOF/VEL on day 8 (week 2) through 84 (week 12) . Post-Treatment follow up through week 12.	HIV/HCV Co-infection: Sofosbuvir/Velpatasvir (SOF/VEL) days 0 through 7 and Paired liver biopsy at days 0 and 7 (cohort 1) or days 0 and 4 (cohort 2). SOF/VEL on day 8 (week 2) through 84 (week 12) . Post-Treatment follow up through week 12.
Period Title: Overall Study
STARTED	5	5	5
COMPLETED	5	5	5
NOT COMPLETED	0	0	0

Baseline Characteristics

Arm/Group Title	Group A	Group B	Group C	Total
Arm/Group Description	Monoinfected: Sofosbuvir/Velpatasvir/Voxilaprevir SOF/VEL/VOX days 0-7 Paired liver biopsy at days 0 and 7 (cohort 1) or days 0 and 4 (cohort 2). SOF/VEL days 8 (week 2) through 84 (week 12). Post-treatment follow up through week 12.	Monoinfected: Sofosbuvir/Velpatasvir (SOF/VEL) days 0 through 7 and Paired liver biopsy at days 0 and 7 (cohort 1) or days 0 and 4 (cohort 2). SOF/VEL on day 8 (week 2) through 84 (week 12) . Post-Treatment follow up through week 12.	HIV/HCV Co-infection: Sofosbuvir/Velpatasvir (SOF/VEL) days 0 through 7 and Paired liver biopsy at days 0 and 7 (cohort 1) or days 0 and 4 (cohort 2). SOF/VEL on day 8 (week 2) through 84 (week 12) . Post-Treatment follow up through week 12.	Total of all reporting groups
Overall Participants	5	5	5	15
Age (years) [Mean (Full Range) ]
Mean (Full Range) [years]	50	47	54.6	50.5
Sex: Female, Male (Count of Participants)
Female	2 40%	3 60%	2 40%	7 46.7%
Male	3 60%	2 40%	3 60%	8 53.3%
Ethnicity (NIH/OMB) (Count of Participants)
Hispanic or Latino	0 0%	0 0%	0 0%	0 0%
Not Hispanic or Latino	5 100%	5 100%	5 100%	15 100%
Unknown or Not Reported	0 0%	0 0%	0 0%	0 0%
Race (NIH/OMB) (Count of Participants)
American Indian or Alaska Native	0 0%	0 0%	0 0%	0 0%
Asian	0 0%	0 0%	0 0%	0 0%
Native Hawaiian or Other Pacific Islander	0 0%	0 0%	0 0%	0 0%
Black or African American	4 80%	3 60%	5 100%	12 80%
White	1 20%	2 40%	0 0%	3 20%
More than one race	0 0%	0 0%	0 0%	0 0%
Unknown or Not Reported	0 0%	0 0%	0 0%	0 0%
Region of Enrollment (participants) [Number]
United States	5 100%	5 100%	5 100%	15 100%

Outcome Measures

1. Primary Outcome

Title	Total Number of HCV-infected Hepatocytes Measured in Liver Tissue Obtained by Liver Biopsy at Day 0 (Pre-treatment) and at Day 7 of Antiviral Therapy
Description	Estimate the total number of HCV-infected Hepatocytes (virus burden) for each participant between pre-treatment liver biopsy and post treatment liver biopsy samples using HCV Quantitative real time PCR. Comparison of total number of HCV-infected Hepatocytes (virus burden) were reported between HCV mono infection and co infection groups.
Time Frame	Pre-treatment, Day 7

Outcome Measure Data

Analysis Population Description

Overall number analyzed is the total hepatocytes analyzed in specific arms but numbers in rows represent only HCV positive Hepatocytes

Arm/Group Title	Group A	Group B	Group C
Arm/Group Description	Monoinfected: Sofosbuvir/Velpatasvir/Voxilaprevir SOF/VEL/VOX days 0-7 Paired liver biopsy at days 0 and 7 (cohort 1) or days 0 and 4 (cohort 2). SOF/VEL days 8 (week 2) through 84 (week 12). Post-treatment follow up through week 12.	Monoinfected: Sofosbuvir/Velpatasvir (SOF/VEL) days 0 through 7 and Paired liver biopsy at days 0 and 7 (cohort 1) or days 0 and 4 (cohort 2). SOF/VEL on day 8 (week 2) through 84 (week 12) . Post-Treatment follow up through week 12.	HIV/HCV Co-infection: Sofosbuvir/Velpatasvir (SOF/VEL) days 0 through 7 and Paired liver biopsy at days 0 and 7 (cohort 1) or days 0 and 4 (cohort 2). SOF/VEL on day 8 (week 2) through 84 (week 12) . Post-Treatment follow up through week 12.
Measure Participants	5	5	5
Measure Hepatocytes	3220	3340	3463
Participant 1 (Group A) Participant 1 (Group B) Participant 1 (Group C)pre trea	45	16	290
Participant 1 (Group A) Participant 1 (Group B) Participant 1 (Group C)pos trea	2	5	7
Participant 2 (Group A) Participant 2 (Group B) Participant 2 (Group C)pre trea	53	11	33
Participant 2 (Group A) Participant 2 (Group B) Participant 2 (Group C)pos trea	0	1	3
Participant 3 (Group A) Participant 3 (Group B) Participant 3 (Group C)pretreat	18	212	216
Participant 3 (Group A) Participant 3 (Group B) Participant 3 (Group C)postreat	2	9	24
Participant 4 (Group A) Participant 4 (Group B) Participant 4 (Group C)pre trea	109	24	13
Participant 4 (Group A) Participant 4 (Group B) Participant 4 (Group C)pos trea	3	1	0
Participant 5 (Group A) Participant 5 (Group B) Participant 5 (Group C)pretre	126	4	74
Participant 5 (Group A) Participant 5 (Group B) Participant 5 (Group C)postre	18	1	12

2. Secondary Outcome

Title	Reduction Over the First Week in Plasma HCV RNA
Description	During one week after treatment with direct-acting antivirals, the decline from the baseline plasma HCV RNA levels observed for each individual participant using HCV Quantitative real time PCR. The level of HCV RNA decline compared to those treated with Sofosbuvir/Velpatasvir (SOF/VEL) vs Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) and between HCV mono infection and HIV/HCV co infection groups.
Time Frame	Pre-treatment, up to 1 week

Outcome Measure Data

Analysis Population Description

Decline plasma levels of HCV RNA from each participant obtained over the first week.

Arm/Group Title	Group A	Group B	Group C
Arm/Group Description	Monoinfected: Sofosbuvir/Velpatasvir/Voxilaprevir SOF/VEL/VOX days 0-7 Paired liver biopsy at days 0 and 7 (cohort 1) or days 0 and 4 (cohort 2). SOF/VEL days 8 (week 2) through 84 (week 12). Post-treatment follow up through week 12.	Monoinfected: Sofosbuvir/Velpatasvir (SOF/VEL) days 0 through 7 and Paired liver biopsy at days 0 and 7 (cohort 1) or days 0 and 4 (cohort 2). SOF/VEL on day 8 (week 2) through 84 (week 12) . Post-Treatment follow up through week 12.	HIV/HCV Co-infection: Sofosbuvir/Velpatasvir (SOF/VEL) days 0 through 7 and Paired liver biopsy at days 0 and 7 (cohort 1) or days 0 and 4 (cohort 2). SOF/VEL on day 8 (week 2) through 84 (week 12) . Post-Treatment follow up through week 12.
Measure Participants	5	5	5
Participant 1 (Group A) Participant 1 (Group B) Participant 1 (Group C)	631	2240	14817.5
Participant 2 (Group A) Participant 2 (Group B) Participant 2 (Group C)	217.75	884.75	635.5
Participant 3 (Group A) Participant 3 (Group B) Participant 3 (Group C)	1029.75	1348500	5327.5
Participant 4 (Group A) Participant 4 (Group B) Participant 4 (Group C)	6617.5	551.5	65075
Participant 5 (Group A) Participant 5 (Group B) Participant 5 (Group C)	2506.5	627.5	12992.5

3. Secondary Outcome

Title	Total Number of HCV-infected Hepatocytes That Express Interferon-stimulated Genes (ISGs) Within the First Week of DAA Therapy Using Single Cell Laser Micro Dissection (scLCM).
Description	Total number of hepatocytes that express interferon-stimulated genes (ISGs) were estimated using Quantitative real time PCR for each participant on pre-treatment and post treatment liver biopsy samples. Comparison of total number of hepatocytes that express interferon-stimulated genes (ISGs) were reported between HCV mono infection and co infection groups.
Time Frame	Pre-treatment, up to 1 week

Outcome Measure Data

Analysis Population Description

Total number of hepatocytes that express interferon-stimulated genes (ISGs) between pre and post treatment

Arm/Group Title	Group A	Group B	Group C
Arm/Group Description	Monoinfected: Sofosbuvir/Velpatasvir/Voxilaprevir SOF/VEL/VOX days 0-7 Paired liver biopsy at days 0 and 7 (cohort 1) or days 0 and 4 (cohort 2). SOF/VEL days 8 (week 2) through 84 (week 12). Post-treatment follow up through week 12.	Monoinfected: Sofosbuvir/Velpatasvir (SOF/VEL) days 0 through 7 and Paired liver biopsy at days 0 and 7 (cohort 1) or days 0 and 4 (cohort 2). SOF/VEL on day 8 (week 2) through 84 (week 12) . Post-Treatment follow up through week 12.	HIV/HCV Co-infection: Sofosbuvir/Velpatasvir (SOF/VEL) days 0 through 7 and Paired liver biopsy at days 0 and 7 (cohort 1) or days 0 and 4 (cohort 2). SOF/VEL on day 8 (week 2) through 84 (week 12) . Post-Treatment follow up through week 12.
Measure Participants	5	5	5
Measure Hepatocytes	904	912	904
Participant 1 (Group A) Participant 1 (Group B) Participant 1 (Group C) Pre Treatment	14	71	41
Participant 1 (Group A) Participant 1 (Group B) Participant 1 (Group C) Post Treatment	8	68	68
Participant 2 (Group A) Participant 2 (Group B) Participant 2 (Group C) Pre Treatment	57	36	39
Participant 2 (Group A) Participant 2 (Group B) Participant 2 (Group C) Post Treatment	62	24	40
Participant 3 (Group A) Participant 3 (Group B) Participant 3 (Group C) Pre Treatment	78	66	55
Participant 3 (Group A) Participant 3 (Group B) Participant 3 (Group C) Post Treatment	83	46	57
Participant 4 (Group A) Participant 4 (Group B) Participant 4 (Group C) Pre Treatment	71	49	36
Participant 4 (Group A) Participant 4 (Group B) Participant 4 (Group C) Post Treatment	71	27	63
Participant 5 (Group A) Participant 5 (Group B) Participant 5 (Group C) Pre Treatment	79	67	34
Participant 5 (Group A) Participant 5 (Group B) Participant 5 (Group C) Post Treatment	72	66	42

4. Secondary Outcome

Title	Amount of HCV RNA Per Infected Hepatocyte Using Single Cell Laser Micro Dissection (scLCM) on Liver Biopsy Specimens, Obtained Just Prior to Treatment Initiation (Pre-treatment), and After the First Week of DAA Therapy.
Description	The HCV RNA levels (viral burden) from each infected hepatocytes were measured using Quantitative Real-Time Polymerase Chain Reaction (PCR) from each participants at pre-treatment and post-treatment. The level of HCV RNA (viral burden) decline were reported from intracellular hepatocytes and compared to those treated with Sofosbuvir/Velpatasvir (SOF/VEL) vs Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) and between HCV mono infection and HIV/HCV co infection groups.
Time Frame	Pre-treatment, after first week

Outcome Measure Data

Analysis Population Description

Amount of HCV RNA levels from individual hepatocytes for each participant obtained at pre-treatment and post treatment.

Arm/Group Title	Group A	Group B	Group C
Arm/Group Description	Monoinfected: Sofosbuvir/Velpatasvir/Voxilaprevir SOF/VEL/VOX days 0-7 Paired liver biopsy at days 0 and 7 (cohort 1) or days 0 and 4 (cohort 2). SOF/VEL days 8 (week 2) through 84 (week 12). Post-treatment follow up through week 12.	Monoinfected: Sofosbuvir/Velpatasvir (SOF/VEL) days 0 through 7 and Paired liver biopsy at days 0 and 7 (cohort 1) or days 0 and 4 (cohort 2). SOF/VEL on day 8 (week 2) through 84 (week 12) . Post-Treatment follow up through week 12.	HIV/HCV Co-infection: Sofosbuvir/Velpatasvir (SOF/VEL) days 0 through 7 and Paired liver biopsy at days 0 and 7 (cohort 1) or days 0 and 4 (cohort 2). SOF/VEL on day 8 (week 2) through 84 (week 12) . Post-Treatment follow up through week 12.
Measure Participants	5	5	5
Participant 1 (Group A) Participant 1 (Group B) Participant 1 (Group C) Pre treat	8.61	7.57	32.7
Participant 1 (Group A) Participant 1 (Group B) Participant 1 (Group C) Post treat	20.91	2.83	37.8
Participant 2 (Group A) Participant 2 (Group B) Participant 2 (Group C)Pre treat	19.74	11.04	18.36
Participant 2 (Group A) Participant 2 (Group B) Participant 2 (Group C)Post treat	0	12.93	8.16
Participant 3 (Group A) Participant 3 (Group B) Participant 3 (Group C)Pre treat	10.35	27.18	30
Participant 3 (Group A) Participant 3 (Group B) Participant 3 (Group C)Post treat	14.76	9.25	15.72
Participant 4 (Group A) Participant 4 (Group B) Participant 4 (Group C)Pre treat	29.25	3.45	14.25
Participant 4 (Group A) Participant 4 (Group B) Participant 4 (Group C)Post treat	9.15	0	0
Participant 5 (Group A) Participant 5 (Group B) Participant 5 (Group C)Pre treat	15.3	2.36	5.49
Participant 5 (Group A) Participant 5 (Group B) Participant 5 (Group C)Post treat	14.55	2.27	4.09

Adverse Events

Time Frame	24 weeks
Adverse Event Reporting Description	adverse events were systematically assessed days 0-7, and week 2 and 4 study visits and as needed. Serious adverse events were systematically assessed at all follow-up visits and as needed.
Arm/Group Title	Group A		Group B		Group C
Arm/Group Description	Monoinfected: Sofosbuvir/Velpatasvir/Voxilaprevir SOF/VEL/VOX days 0-7 Paired liver biopsy at days 0 and 7 (cohort 1) or days 0 and 4 (cohort 2). SOF/VEL days 8 (week 2) through 84 (week 12). Post-treatment follow up through week 12.		Monoinfected: Sofosbuvir/Velpatasvir (SOF/VEL) days 0 through 7 and Paired liver biopsy at days 0 and 7 (cohort 1) or days 0 and 4 (cohort 2). SOF/VEL on day 8 (week 2) through 84 (week 12) . Post-Treatment follow up through week 12.		HIV/HCV Co-infection: Sofosbuvir/Velpatasvir (SOF/VEL) days 0 through 7 and Paired liver biopsy at days 0 and 7 (cohort 1) or days 0 and 4 (cohort 2). SOF/VEL on day 8 (week 2) through 84 (week 12) . Post-Treatment follow up through week 12.
All Cause Mortality
	Group A		Group B		Group C
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	0/5 (0%)		0/5 (0%)		0/5 (0%)
Serious Adverse Events
	Group A		Group B		Group C
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	0/5 (0%)		0/5 (0%)		0/5 (0%)
Other (Not Including Serious) Adverse Events
	Group A		Group B		Group C
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	2/5 (40%)		2/5 (40%)		3/5 (60%)
Gastrointestinal disorders
Fatigue	1/5 (20%)	3	0/5 (0%)	0	0/5 (0%)	0
Vomiting	0/5 (0%)	0	1/5 (20%)	1	0/5 (0%)	0
General disorders
Flu-like symptoms	0/5 (0%)	0	1/5 (20%)	1	0/5 (0%)	0
Akathisia	0/5 (0%)	0	0/5 (0%)	0	1/5 (20%)	1
Metabolism and nutrition disorders
Dehydration	0/5 (0%)	0	0/5 (0%)	0	1/5 (20%)	1
Musculoskeletal and connective tissue disorders
Arthralgia	0/5 (0%)	0	1/5 (20%)	1	0/5 (0%)	0
Nervous system disorders
Headache	1/5 (20%)	2	1/5 (20%)	1	0/5 (0%)	0
Dysgeusia	1/5 (20%)	2	0/5 (0%)	0	0/5 (0%)	0
Pregnancy, puerperium and perinatal conditions
Pregnancy	0/5 (0%)	0	1/5 (20%)	1	0/5 (0%)	0
Psychiatric disorders
Insomnia	0/5 (0%)	0	0/5 (0%)	0	1/5 (20%)	1
Skin and subcutaneous tissue disorders
Pruritus	0/5 (0%)	0	0/5 (0%)	0	1/5 (20%)	1

Limitations/Caveats

This study is based on a relatively small sample of the liver

More Information

Certain Agreements

All Principal Investigators ARE employed by the organization sponsoring the study.

There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.